Cardiff Oncology Seeks Shareholder Approval to Nearly Double Authorized Shares to 320M
CRDF sits 33% above its 52-week low of $0.757.
Summary
Cardiff Oncology filed a definitive proxy seeking approval to nearly double authorized shares to 320M, citing obligations under its July 2026 financing agreement. The vote is scheduled for October 22, 2026.
Key Events · Corporate Governance and Compliance · CRDF
-
Authorized Share Increase Proposed
Proposal 1 seeks to increase authorized capital stock from 170M to 320M shares and common stock from 150M to 300M shares, nearly doubling the current authorization.
-
Financing Agreement Obligation
The board states the amendment is required under the Securities Purchase Agreement entered July 14, 2026, in connection with the company's recent $10M registered direct offering.
-
Dilution Headroom Created
With 77.8M shares outstanding, approval would create headroom for approximately 222M additional common shares — a substantial overhang for future financings, warrant exercises, and equity awards.
-
Existing Shelf and ATM Programs
The company already has a $400M universal shelf registration and a $150M ATM program with Jefferies, under which only 132,274 shares have been sold for $0.2M net proceeds to date.
Analysis · CRDF · Life Sciences
Cardiff Oncology is asking shareholders to approve a near-doubling of authorized shares — from 170M to 320M total capital stock, and from 150M to 300M common shares. The company states this is required under the July 14, 2026 Securities Purchase Agreement tied to its recent $10M financing. With 77.8M shares outstanding, the increase creates headroom for roughly 222M additional common shares — a massive overhang that could fund future dilution. The company already has a $400M shelf and a $150M ATM program in place, and the proxy explicitly lists financing transactions, warrant exercises, and equity incentive plans as anticipated uses. Against a backdrop of a going-concern warning and an existential license dispute over onvansertib, this vote is effectively a referendum on the company's ability to raise survival capital. The special meeting is set for October 22, 2026.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDF was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.4M. The 52-week trading range was $0.76 to $3.31. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.